DaVita Other Non-Current Liabilities 2010-2024 | DVA
DaVita other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- DaVita other non-current liabilities for the quarter ending December 31, 2024 were $0.170B, a 7.37% decline year-over-year.
- DaVita other non-current liabilities for 2024 were $0.17B, a 7.37% decline from 2023.
- DaVita other non-current liabilities for 2023 were $0.183B, a 73.97% increase from 2022.
- DaVita other non-current liabilities for 2022 were $0.105B, a 11.69% decline from 2021.
DaVita Annual Other Non-Current Liabilities
(Millions of US $) |
| 2024 |
$170 |
| 2023 |
$183 |
| 2022 |
$105 |
| 2021 |
$119 |
| 2020 |
$150 |
| 2019 |
$161 |
| 2018 |
$451 |
| 2017 |
$365 |
| 2016 |
$746 |
| 2015 |
$439 |
| 2014 |
$390 |
| 2013 |
$380 |
| 2012 |
$458 |
| 2011 |
$152 |
| 2010 |
$115 |
| 2009 |
$118 |
DaVita Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-12-31 |
$170 |
| 2024-09-30 |
$183 |
| 2024-06-30 |
$179 |
| 2024-03-31 |
$180 |
| 2023-12-31 |
$183 |
| 2023-09-30 |
$185 |
| 2023-06-30 |
$183 |
| 2023-03-31 |
$100 |
| 2022-12-31 |
$105 |
| 2022-09-30 |
$107 |
| 2022-06-30 |
$105 |
| 2022-03-31 |
$109 |
| 2021-12-31 |
$119 |
| 2021-09-30 |
$163 |
| 2021-06-30 |
$158 |
| 2021-03-31 |
$151 |
| 2020-12-31 |
$150 |
| 2020-09-30 |
$147 |
| 2020-06-30 |
$144 |
| 2020-03-31 |
$162 |
| 2019-12-31 |
$161 |
| 2019-09-30 |
$135 |
| 2019-06-30 |
$135 |
| 2019-03-31 |
$144 |
| 2018-12-31 |
$451 |
| 2018-09-30 |
$452 |
| 2018-06-30 |
$418 |
| 2018-03-31 |
$391 |
| 2017-12-31 |
$365 |
| 2017-09-30 |
$548 |
| 2017-06-30 |
$521 |
| 2017-03-31 |
$504 |
| 2016-12-31 |
$746 |
| 2016-09-30 |
$421 |
| 2016-06-30 |
$421 |
| 2016-03-31 |
$464 |
| 2015-12-31 |
$439 |
| 2015-09-30 |
$406 |
| 2015-06-30 |
$400 |
| 2015-03-31 |
$407 |
| 2014-12-31 |
$390 |
| 2014-09-30 |
$368 |
| 2014-06-30 |
$386 |
| 2014-03-31 |
$407 |
| 2013-12-31 |
$380 |
| 2013-09-30 |
$364 |
| 2013-06-30 |
$372 |
| 2013-03-31 |
$511 |
| 2012-12-31 |
$458 |
| 2012-09-30 |
$161 |
| 2012-06-30 |
$164 |
| 2012-03-31 |
$158 |
| 2011-12-31 |
$152 |
| 2011-09-30 |
$156 |
| 2011-06-30 |
$127 |
| 2011-03-31 |
$111 |
| 2010-12-31 |
$115 |
| 2010-09-30 |
$117 |
| 2010-06-30 |
$118 |
| 2010-03-31 |
$119 |
| 2009-12-31 |
$118 |
| 2009-09-30 |
$133 |
| 2009-06-30 |
$134 |
| 2009-03-31 |
$135 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$11.363B |
$12.816B |
|
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.
|
